Emmaus Life Sciences Inc (OTCQX:EMMA) CEO Yutaka Niihara tells Proactive the group reported its 3Q financial results, showing that the company generated revenue of $5.8 million, up 3% from $5.6 million during the corresponding period last year. The results showed the company is progressing its efforts to expand access to Endari, the firm’s prescription L-glutamine oral powder for the treatment of sickle cell disease. Niihara says he expects its recently established partnerships with UpScript, and Asembia to generate further growth.
Emmaus Life Sciences reports uptick in 3Q topline growth as its ramps up access to its sickle cell disease drug
